Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.78 |
| ▸ | CD38 | P28907 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6187321 | 0.82 | MAP3K8 (0.66) | EGFRERBB2 | |
| SCHEMBL6190384 | 0.81 | CD38 (0.74) | EGFRCD38ERBB2 | |
| Hydrochloric Acid SCHEMBL6186793 | 0.78 | EGFR (0.67) | EGFRCD38ERBB2 | |
| SCHEMBL7760849 | 0.77 | EGFR (0.68) | EGFRERBB2 | |
| SCHEMBL6187564 | 0.77 | EGFR (0.62) | EGFRCD38ERBB2 | |
| SCHEMBL27459248 | 0.76 | EGFR (0.66) | EGFRCD38ERBB2 | |
| SCHEMBL31299934 | 0.76 | EGFR (1.00) | EGFRCD38ERBB2 | |
| SCHEMBL29923578 | 0.76 | EGFR (1.00) | EGFRCD38ERBB2 | |
| SCHEMBL6188729 | 0.76 | EGFR (0.77) | EGFRCD38ERBB2NPC1 | |
| SCHEMBL2991833 | 0.76 | EGFR (1.00) | EGFRCD38ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897214-B2 | Quinazoline derivatives | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| EP-0880507-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| CN-1142919-C | Quinazoline derivatives as antitumor agents | — | 2004-03-24 | — | — | CN | disclosed |
| US-20030018029-A1 | Quinazoline derivatives | ZENECA LIMITED | 2003-01-23 | — | — | US | disclosed |
| US-6399602-B1 | ANTICANCER AGENTS | ZENECA LIMITED (GB) | 2002-06-04 | — | — | US | disclosed |
| CN-1211240-A | Quinazoline derivatives as antitumor agents | ZENECA LTD (GB) | 1999-03-17 | — | — | CN | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018029-A1 | Quinazoline derivatives | ABL1, FGFR1, ERBB2 | EGFR 25/4885CD38 1297/4885CLK4 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.